GMED Globus Medical
- 63.240
- -0.510-0.80%
Globus Medical News
There May Be Reason For Hope In Globus Medical's (NYSE:GMED) Disappointing Earnings
Globus Medical, Inc.'s (NYSE:GMED) recent soft profit numbers didn't appear to worry shareholders, as the stock price showed strength. However, we think the company is showing some signs that things
Morgan Stanley Raises Price Target on Globus Medical to $67 From $57, Keeps Equalweight Rating
Globus Medical (GMED) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $55 to $85. Price: 62.33, Change: -2.40, Percent Change: -3.70
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Globus Medical (GMED) and DENTSPLY SIRONA (XRAY)
Truist Financial Keeps Their Hold Rating on Globus Medical (GMED)
Globus Medical(GMED.US) Director Sells US$1.3 Million in Common Stock
$Globus Medical(GMED.US)$ Director Davidar David D sold 20,000 shares of common stock on May 8, 2024 at an average price of $65 for a total value of $1.3 million.Source: Announcement What is statement
Globus Medical Insider Sold Shares Worth $1,300,000, According to a Recent SEC Filing
David D Davidar, Director, on May 08, 2024, sold 20,000 shares in Globus Medical (GMED) for $1,300,000. Following the Form 4 filing with the SEC, Davidar has control over a total of 772,242 shares of
Form 144 | Globus Medical(GMED.US) Director Proposes to Sell 3.39 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $Globus Medical(GMED.US)$ Director Lemaitre Dan intends to sell 52,500 shares of its common stock on May 10, with a total market value of approximately $3.39 million.
Form 144 | Globus Medical(GMED.US) Director Proposes to Sell 693.78K in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $Globus Medical(GMED.US)$ Director Lemaitre Dan intends to sell 10,800 shares of its common stock on May 10, with a total market value of approximately $693.78K. Sou
Key Takeaways From Globus Medical Analyst Ratings
Globus Medical (NYSE:GMED) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.In the table below, you'll find a summary of their recent ra
Globus Medical Is Maintained at Overweight by Barclays
Globus Medical Is Maintained at Overweight by Barclays
Globus Medical Price Target Raised to $85.00/Share From $83.00 by Barclays
Globus Medical Price Target Raised to $85.00/Share From $83.00 by Barclays
Barclays Maintains Overweight on Globus Medical, Raises Price Target to $85
Barclays analyst Matt Miksic maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $83 to $85.
Barclays Reaffirms Their Buy Rating on Globus Medical (GMED)
Globus Medical's Strong Quarter Tempered by NuVasive Merger Complexities: A Hold Rating
Form 144 | Globus Medical(GMED.US) Director Proposes to Sell 227.32K in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Globus Medical(GMED.US)$ Director Davidar David D intends to sell 3,500 shares of its common stock on May 8, with a total market value of approximately $227.32K. Sou
Form 144 | Globus Medical(GMED.US) Director Proposes to Sell 1.3 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Globus Medical(GMED.US)$ Director Davidar David D intends to sell 20,000 shares of its common stock on May 8, with a total market value of approximately $1.3 million.
Globus Medical Shares Race Higher After Better-Than-Expected Q1 Results
Globus Medical, Inc. (NYSE:GMED) shares are trading higher Wednesday after the company posted better-than-expected first-quarter financial results and raised its fiscal year 2024 guidance. The Details
Sector Update: Health Care Stocks Slipping Wednesday Afternoon
Health care stocks were declining Wednesday afternoon, with the NYSE Health Care Index down 0.4% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.3%. The iShares Biotechnology ETF (IBB)
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial results and issued second-quarter revenue guidance below estim
Sector Update: Health Care
Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.4%. The iShares Biotechnology ETF (IBB) fell
Analysis
Price Target
No Data
